Publications
- Komentář k analýze2023 | First Faculty of Medicine
- Indikace durvalumabu v léčbě pacientů s bronchogenním karcinomem2023 | First Faculty of Medicine
- Tříleté výsledky studie CheckMate 9LA: komentář ke studii a klinická zkušenost2022 | First Faculty of Medicine
- Clinical experience with durvalumab treatment2021 | First Faculty of Medicine
- Cemiplimab in the treatment of NSCLC: EMPOWER-Lung 1 trial2021 | First Faculty of Medicine
- What approach to ALK-positive NSCLC?2020 | First Faculty of Medicine, Faculty of Medicine in Pilsen
- The role of durvalumab in the treatment of stage III NSCLC2020 | First Faculty of Medicine
- Screening karcinomu plic - screeningové studie2020 | First Faculty of Medicine
- CCL2, CCL8, CXCL12 chemokines in resectable non-small cell lung cancer (NSCLC)2023 | First Faculty of Medicine, Central Library of Charles University, Third Faculty of Medicine
- Komentář ke studii2023 | First Faculty of Medicine
Loading network view...